Economical Value of Vaccines for the Developing Countries--The Case of Instituto Butantan, a Public Institution in Brazil e1300

The companies are understandably reluctant to create competitors with knowledge and capabilities in the most up-to-date production methods and most advanced vaccines. [...]the developing country partner may obtain out-of-date technology for older vaccines. Besides this, a federal regulatory agency (...

Full description

Saved in:

Bibliographic Details
Published in:	PLoS neglected tropical diseases Vol. 5; no. 11
Main Authors:	Ho, Paulo Lee, Miyaji, Eliane Namie, Oliveira, Maria LeonorSarno, Dias, Waldely deOliveira, Kubrusly, Flavia Saldanha, Tanizaki, Martha Massako, Martins, Elizabeth AngélicaLeme, Raw, Isaias
Format:	Journal Article
Language:	English
Published:	San Francisco Public Library of Science 01-11-2011
Subjects:	Agreements Developing countries Federal regulation Immunization LDCs Technology transfer Tropical diseases Vaccines Brazil
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The companies are understandably reluctant to create competitors with knowledge and capabilities in the most up-to-date production methods and most advanced vaccines. [...]the developing country partner may obtain out-of-date technology for older vaccines. Besides this, a federal regulatory agency (ANVISA) was created that certifies the production laboratories and promotes a move to full compliance with WHO GMP guidance, a process that is not instantaneous but depends on investments that the MH began to make available starting in 1985. [...]the country should ensure the capability to undertake rigorous epidemiological studies to guide and evaluate the delivery of vaccination services.
ISSN:	1935-2727 1935-2735
DOI:	10.1371/journal.pntd.0001300